Janmaat, Vincent T. Bruno, Marco J. Polinder, Suzanne Lorenzen, Sylvie Lordick, Florian Peppelenbosch, Maikel P. Spaander, Manon C. W. Cost effectiveness model as described in the manuscript. <p>(XLSX)</p> cisplatin;cetuximab;cell carcinoma;threshold;cost effectiveness analysis model;ratio;cell carcinoma addition;esophageal;Monte Carlo analysis;regimen;Sensitivity analysis;Advanced Esophageal Squamous Cell Carcinoma Background;phase II trial;data 2016-04-21
    https://plos.figshare.com/articles/dataset/Cost_Effectiveness_of_Cetuximab_for_Advanced_Esophageal_Squamous_Cell_Carcinoma/3194605
10.1371/journal.pone.0153943.s001